Amyotrophic lateral sclerosis carries a median survival of 2-5 years from symptom onset, with respiratory failure the cause of death in up to 95% of patients. CDC-supported estimates placed the number of people living with ALS in the United States at 32,893 in 2022, with projected cases rising to 36,308 by 2030. In a Medicare claims study using the broadest case definition, 40.1% survived less than one year after diagnosis, 25.5% dying within six months, and fewer than 39.7% ever had an ALS diagnosis recorded by a neurologist. These findings suggest that restrictive case definitions may undercount older and marginalized adults with ALS.
AAVBC's ALS Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity (G12.21 vs. G12.20) and HCC 190/RAF mapping, Gold Coast and revised El Escorial diagnostic criteria, ALSFRS-R and King's College staging, geriatric risk factors and subtle early signs, MEAT documentation standards, and AAN-aligned multidisciplinary treatment across respiratory, nutritional, and cognitive domains. Grounded in AAN guidance and current CMS coding requirements, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations early and document disease progression with the specificity risk adjustment requires.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of ALS — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Amyotrophic lateral sclerosis carries a median survival of 2-5 years from symptom onset, with respiratory failure the cause of death in up to 95% of patients. CDC-supported estimates placed the number of people living with ALS in the United States at 32,893 in 2022, with projected cases rising to 36,308 by 2030. In a Medicare claims study using the broadest case definition, 40.1% survived less than one year after diagnosis, 25.5% dying within six months, and fewer than 39.7% ever had an ALS diagnosis recorded by a neurologist. These findings suggest that restrictive case definitions may undercount older and marginalized adults with ALS.
AAVBC's ALS Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity (G12.21 vs. G12.20) and HCC 190/RAF mapping, Gold Coast and revised El Escorial diagnostic criteria, ALSFRS-R and King's College staging, geriatric risk factors and subtle early signs, MEAT documentation standards, and AAN-aligned multidisciplinary treatment across respiratory, nutritional, and cognitive domains. Grounded in AAN guidance and current CMS coding requirements, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations early and document disease progression with the specificity risk adjustment requires.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of ALS — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
